Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ: VNDA · Real-Time Price · USD
6.06
-0.07 (-1.14%)
Jun 3, 2026, 1:38 PM EDT - Market open
Vanda Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 217.78 | 216.11 | 198.77 | 192.64 | 254.38 | 268.68 | |
Revenue Growth (YoY) | 8.16% | 8.72% | 3.18% | -24.27% | -5.32% | 8.27% |
Cost of Revenue | 12.68 | 13.04 | 11.31 | 14.8 | 24.28 | 25.63 |
Gross Profit | 205.1 | 203.06 | 187.46 | 177.84 | 230.1 | 243.05 |
Selling, General & Admin | 256.23 | 237.95 | 146.41 | 112.88 | 136.49 | 124.05 |
Depreciation & Amortization Expenses | 7.24 | 7.01 | 7.27 | 2.09 | 1.52 | 1.48 |
Research & Development | 101.99 | 109.27 | 74.43 | 76.82 | 85.77 | 75.36 |
Total Operating Expenses | 365.46 | 354.23 | 228.12 | 191.8 | 223.77 | 200.89 |
Operating Income | -160.36 | -151.17 | -40.66 | -13.95 | 6.33 | 42.17 |
Total Non-Operating Income (Expense) | 10.66 | 12.52 | 17.74 | 20.29 | 4.97 | 0.2 |
Pretax Income | -149.7 | -138.65 | -22.92 | 6.34 | 11.3 | 42.36 |
Provision for Income Taxes | 89.84 | 81.83 | -4.02 | 3.83 | 5.03 | 9.21 |
Net Income | -239.55 | -220.47 | -18.9 | 2.51 | 6.28 | 33.15 |
Net Income to Common | -239.55 | -220.47 | -18.9 | 2.51 | 6.28 | 33.15 |
Net Income Growth | - | - | - | -60.02% | -81.07% | 42.06% |
Shares Outstanding (Basic) | 59 | 59 | 58 | 57 | 56 | 56 |
Shares Outstanding (Diluted) | 59 | 59 | 58 | 58 | 57 | 57 |
Shares Change (YoY) | 1.43% | 1.34% | 1.03% | 1.01% | 0.11% | 3.14% |
EPS (Basic) | -4.05 | -3.74 | -0.33 | 0.04 | 0.11 | 0.60 |
EPS (Diluted) | -4.05 | -3.74 | -0.33 | 0.04 | 0.11 | 0.58 |
EPS Growth | - | - | - | -63.64% | -81.03% | 38.09% |
Shares Outstanding | 60.14 | 59.1 | 58.31 | 57.53 | 56.78 | 55.9 |
Free Cash Flow | -127.3 | -110.44 | -16.25 | 12.42 | 31.31 | 63.66 |
Free Cash Flow Growth | - | - | - | -60.33% | -50.83% | 27.38% |
Free Cash Flow Per Share | -2.15 | -1.87 | -0.28 | 0.22 | 0.55 | 1.12 |
Gross Margin | 94.18% | 93.96% | 94.31% | 92.32% | 90.45% | 90.46% |
Operating Margin | -73.64% | -69.95% | -20.46% | -7.24% | 2.49% | 15.69% |
Profit Margin | -109.99% | -102.02% | -9.51% | 1.30% | 2.47% | 12.34% |
FCF Margin | -58.45% | -51.10% | -8.17% | 6.45% | 12.31% | 23.69% |
EBITDA | -150.71 | -139.25 | -30.86 | -9.62 | 9.06 | 45.01 |
EBITDA Margin | -69.20% | -64.44% | -15.53% | -4.99% | 3.56% | 16.75% |
EBIT | -160.36 | -151.17 | -40.66 | -13.95 | 6.33 | 42.17 |
EBIT Margin | -73.64% | -69.95% | -20.46% | -7.24% | 2.49% | 15.69% |
Effective Tax Rate | -60.01% | -59.02% | 17.54% | 60.42% | 44.47% | 21.74% |